Cargando…

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses

INTRODUCTION: Dolutegravir is a second generation integrase inhibitor with a proposed high genetic barrier to resistance. However, in clinical trials, decreased virological response was seen in a subset of patients with prior exposure to raltegravir and multiple integrase resistance mutations. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marije Hofstra, Laura, Nijhuis, Monique, Mudrikova, Tania, Fun, Axel, Schipper, Pauline, Schneider, Margriet, Wensing, Annemarie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P223
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225339/ https://www.ncbi.nlm.nih.gov/pubmed/25397500 http://dx.doi.org/10.7448/IAS.17.4.19755

Ejemplares similares

Acute coronary syndromes in the era of SARS-CoV-2 Infection: A registry of the French group of acute cardiac care
por: Koutsoukis, A., et al.
Publicado: (2021)

Pneumopathie aigue bacterienne et infection vih chez l'enfant en milieu tropical
por: Orega, M., et al.
Publicado: (1999)

CARACTERIZAÇÃO CLÍNICO-EPIDEMIOLÓGICA DE PACIENTES COM COVID-19 COINFECTADOS COM TRICHOSPORON SPP EM HOSPITAL PRIVADO DE SÃO PAULO
por: Moura, Maria Luísa Do Nascimento, et al.
Publicado: (2022)

ARBOVIROSES, NO ESTADO DA BAHIA, DURANTE A PANDEMIA DE COVID 19: UM ESTUDO COMPARATIVO
por: Lopo, Luiza Helena Castro Souza, et al.
Publicado: (2022)

Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients
por: Hofstra, Laura Marije, et al.
Publicado: (2014)

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
por: Schultze, Anna, et al.
Publicado: (2014)

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients
por: Hofstra, L. Marije, et al.
Publicado: (2017)

HIV drug resistance surveillance in low- and middle-income countries: 2004 to 2010
por: Bertagnolio, S, et al.
Publicado: (2012)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

Human Immunodeficiency Virus gag and protease: partners in resistance
por: Fun, Axel, et al.
Publicado: (2012)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Clinical and socio-demographic predictors for virologic failure in rural Southern Africa: preliminary findings from CART-1
por: Daniel Labhardt, Niklaus, et al.
Publicado: (2014)

A retrospective observational study of low-level viraemia and its immunological and virological significance: which outcome to expect
por: Silva, Joana, et al.
Publicado: (2014)

Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study
por: Leierer, Gisela, et al.
Publicado: (2014)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

The absolute lymphocyte count accurately estimates CD4 counts in HIV-infected adults with virologic suppression and immune reconstitution
por: Young, Barnaby, et al.
Publicado: (2014)

Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials
por: Reeves, Iain, et al.
Publicado: (2014)

Acute HIV infection (AHI) in a specialized clinical setting: case-finding, description of virological, epidemiological and clinical characteristics
por: Ammassari, Adriana, et al.
Publicado: (2014)

Socio-economic factors and virological suppression among people diagnosed with HIV in the United Kingdom: results from the ASTRA study
por: Burch, Lisa, et al.
Publicado: (2014)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART
por: Kiselinova, Maja, et al.
Publicado: (2014)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy
por: Erdbeer, Gesa, et al.
Publicado: (2014)

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
por: Montes, Marisa, et al.
Publicado: (2014)

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS study
por: Trottier, Benoit, et al.
Publicado: (2014)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Presenting INIS
por: International Atomic Energy Agency. Vienna
Publicado: (1992)

Presenting INIS
por: International Atomic Energy Agency. Vienna
Publicado: (1996)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t5ig246kp809oautigd1mso03c